Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, Truist Financial Analyst Says

Zymeworks (NASDAQ:ZYME) had its price objective upped by equities research analysts at Truist Financial from $35.00 to $36.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial‘s price target would suggest a potential upside of 14.89% from the company’s current price.

A number of other brokerages have also commented on ZYME. Jefferies Financial Group reissued a “buy” rating and issued a $52.00 price objective on shares of Zymeworks in a research report on Friday, October 23rd. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on Zymeworks in a research report on Wednesday, August 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research report on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Zymeworks in a report on Monday, October 26th. Finally, Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a report on Friday, August 7th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.83.

Zymeworks Stock Performance

Zymeworks stock traded up $0.53 during trading hours on Tuesday, reaching $31.34. 416,053 shares of the company’s stock traded hands, compared to its average volume of 777,676. Zymeworks has a fifty-two week low of $18.20 and a fifty-two week high of $31.97. The firm’s 50 day moving average is $27.46 and its 200-day moving average is $25.38. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -15.48 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME) last released its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%. The business had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The firm’s revenue was up 828.7% on a year-over-year basis. Analysts predict that Zymeworks will post 1.32 EPS for the current year.

Insider Activity

In other news, EVP Adam Schayowitz sold 13,832 shares of the firm’s stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the transaction, the executive vice president directly owned 23,205 shares in the company, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is currently owned by corporate insiders.

Institutional Trading of Zymeworks

A number of hedge funds have recently made changes to their positions in ZYME. Deutsche Bank AG purchased a new position in shares of Zymeworks in the second quarter valued at about $10,383,000. Bank of America Corp DE purchased a new position in shares of Zymeworks in the 2nd quarter worth about $5,727,000. Rubric Capital Management LP raised its holdings in Zymeworks by 21.7% in the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock worth $175,280,000 after acquiring an additional 1,250,000 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Zymeworks during the second quarter valued at $1,128,000. Finally, Jupiter Topco LLC purchased a new stake in Zymeworks in the second quarter worth approximately $476,000. 92.89% of the stock is owned by institutional investors.

More Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: HC Wainwright raised its price target to $56 from $55 and maintained a Buy rating, signaling substantial potential upside in the analyst’s view. Tickerreport article
• Positive Sentiment: Zymeworks raised its 2026 earnings guidance, a favorable update for the company’s near-term outlook. 2026 earnings guidance article
• Neutral Sentiment: Q3 results showed a sharp swing to profit, with EPS of $2.28 versus a loss a year earlier. Revenue was reported above estimates. A $250 million milestone payment from Jazz Pharmaceuticals contributed to the profit, so investors may view some of the results as nonrecurring. Milestone and earnings article
• Negative Sentiment: EPS beat one cited consensus estimate of $2.27 by a penny, but missed the Zacks estimate of $2.40, leaving the earnings comparison mixed. Zacks earnings article

Zymeworks Company Profile

Zymeworks Inc is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses.

The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.